🇺🇸 FDA
Patent

US 11891607

Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors

granted A61KA61K31/4535A61K31/565

Quick answer

US patent 11891607 (Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors) held by REGENERON PHARMACEUTICALS, INC. expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/4535, A61K31/565, A61K31/57, A61K31/663